Biovie Inc. financial data

Symbol
BIVI on Nasdaq
Industry
Pharmaceutical Preparations
Location
680 W Nye Lane, Suite 201, Carson City, NV
State of incorporation
NV
Fiscal year end
June 30
Former names
NANOANTIBIOTICS, INC. (to 7/22/2016)
Latest financial report
10-Q - Q3 2024 - Nov 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 223 % -21.6%
Debt-to-equity 78.1 % -31.5%
Return On Assets -103 % +23.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 7.96M shares -78.9%
Common Stock, Shares, Outstanding 7.96M shares -78.4%
Entity Public Float 20.6M USD
Common Stock, Value, Issued 6.41K USD +73.6%
Weighted Average Number of Shares Outstanding, Basic 6.4M shares +74.2%
Weighted Average Number of Shares Outstanding, Diluted 6.4M shares +74.2%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 16.2M USD -54.2%
Operating Income (Loss) -25.4M USD +46%
Nonoperating Income (Expense) -136K USD -118%
Net Income (Loss) Attributable to Parent -25.6M USD +49.4%
Earnings Per Share, Basic -5.08 USD/shares +71.8%
Earnings Per Share, Diluted -5.08 USD/shares +71.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 20M USD -5.62%
Other Assets, Current 285K USD +565%
Assets, Current 20.2M USD -11.5%
Operating Lease, Right-of-Use Asset 391K USD +452%
Intangible Assets, Net (Excluding Goodwill) 350K USD -39.6%
Goodwill 346K USD 0%
Other Assets, Noncurrent 4.56K USD
Assets 21.2M USD -10.6%
Accounts Payable, Current 3.45M USD +27.2%
Liabilities, Current 6.84M USD -48.2%
Operating Lease, Liability, Noncurrent 333K USD +1001%
Other Liabilities, Noncurrent 48.4K USD
Liabilities 7.17M USD -55.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax 177K USD
Retained Earnings (Accumulated Deficit) -339M USD -8.58%
Stockholders' Equity Attributable to Parent 14.1M USD +86.4%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 26.1M USD +62.3%
Liabilities and Equity 21.2M USD -10.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.58M USD +70.6%
Net Cash Provided by (Used in) Financing Activities -241K USD +59.4%
Net Cash Provided by (Used in) Investing Activities 14.5M USD
Common Stock, Shares Authorized 800M shares 0%
Common Stock, Shares, Issued 7.98M shares -78.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 20M USD -5.62%
Interest Paid, Excluding Capitalized Interest, Operating Activities 137K USD -74.1%
Deferred Tax Assets, Valuation Allowance 69.6M USD +14.9%
Operating Lease, Liability 396K USD +416%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -26.8M USD +47%
Lessee, Operating Lease, Liability, to be Paid 546K USD +551%
Operating Lease, Liability, Current 63.7K USD +36.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 122K USD +173%
Lessee, Operating Lease, Liability, to be Paid, Year One 89.2K USD +127%
Operating Lease, Weighted Average Discount Rate, Percent 0.15 pure +37.2%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 150K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 126K USD
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 131K USD
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 229K USD 0%
Depreciation, Depletion and Amortization 57.3K USD 0%
Interest Expense 2.15M USD -49.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%